{"product_id":"hospital-care-collaboration-and-licensing-deals-2016-2023","title":"Hospital Care Collaboration and Licensing Deals 2016-2023","description":"\u003cp\u003eHospital Care Collaboration and Licensing Deals 2016-2023\u003cbr\u003e\nHospital Care Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the hospital care deals entered into by the worlds leading biopharma companies.\u003c\/p\u003e\n\n\u003cp\u003eFully revised and updated, the report provides details of hospital care deals from 2016 to 2023.\u003c\/p\u003e\n\n\u003cp\u003eThe report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.\u003c\/p\u003e\n\n\u003cp\u003eUnderstanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred – contract documents provide this insight where press releases and databases do not.\u003c\/p\u003e\n\n\u003cp\u003eThis report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.\u003c\/p\u003e\n\n\u003cp\u003eThe initial chapters of this report provide an orientation of hospital care dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in hospital care dealmaking.\u003c\/p\u003e\n\n\u003cp\u003eChapter 3 covers the financial deal terms for deals signed in the hospital care field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.\u003c\/p\u003e\n\n\u003cp\u003eChapter 4 provides a review of the top 25 most active biopharma companies in hospital care dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.\u003c\/p\u003e\n\n\u003cp\u003eChapter 5 provides a comprehensive and detailed review of hospital care deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.\u003c\/p\u003e\n\n\u003cp\u003eChapter 6 provides a comprehensive directory of hospital care deals listed by theraeutic target.\u003c\/p\u003e\n\n\u003cp\u003eThe report also includes numerous table and figures that illustrate the trends and activities in hospital care deal making since 2016.\u003c\/p\u003e\n\n\u003cp\u003eIn addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.\u003c\/p\u003e\n\n\u003cp\u003eKey benefits\u003c\/p\u003e\n\n\u003cp\u003eHospital Care Collaboration and Licensing Deals provides the reader with the following key benefits:\u003c\/p\u003e\n\n\u003cp\u003eUnderstand deal trends since 2016\u003cbr\u003e\nBrowse hospital care collaboration and licensing deals\u003cbr\u003e\nBenchmark analysis – identify market value of transactions\u003cbr\u003e\nFinancials terms - upfront, milestone, royalties\u003cbr\u003e\nDirectory of deals by company A-Z, therapy focus and technology type\u003cbr\u003e\nLeading deals by value\u003cbr\u003e\nMost active dealmakers\u003cbr\u003e\nIdentify assets and deal terms for each transaction\u003cbr\u003e\nAccess contract documents - insights into deal structures\u003cbr\u003e\nDue diligence - assess suitability of your proposed deal terms for partner companies\u003cbr\u003e\nSave hundreds of hours of research time\u003c\/p\u003e\n\n\u003cp\u003eReport scope\u003c\/p\u003e\n\n\u003cp\u003eHospital Care Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of hospital care trends and structure of deals entered into by leading biopharma companies worldwide.\u003c\/p\u003e\n\n\u003cp\u003eHospital Care Collaboration and Licensing Deals includes:\u003c\/p\u003e\n\n\u003cp\u003eTrends in hospital care dealmaking in the biopharma industry\u003cbr\u003e\nOverview of collaboration and licensing deal structure\u003cbr\u003e\nDirectory of hospital care deal records covering pharmaceutical and biotechnology\u003cbr\u003e\nThe leading hospital care deals by value\u003cbr\u003e\nMost active hospital care licensing dealmakers\u003cbr\u003e\nIn Hospital Care Collaboration and Licensing Deals, the available deals are listed by:\u003c\/p\u003e\n\n\u003cp\u003eCompany A-Z\u003cbr\u003e\nHeadline value\u003cbr\u003e\nTherapeutic area\u003cbr\u003e\nTechnology type\u003c\/p\u003e\n\n\u003cp\u003eEach deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.\u003c\/p\u003e\n\n\u003cp\u003eHospital Care Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.\u003c\/p\u003e\n\n\u003cp\u003eAnalyzing contract agreements allows due diligence of:\u003c\/p\u003e\n\n\u003cp\u003eWhat are the precise rights granted or optioned?\u003cbr\u003e\nWhat is actually granted by the agreement to the partner company?\u003cbr\u003e\nWhat exclusivity is granted?\u003cbr\u003e\nWhat is the payment structure for the deal?\u003cbr\u003e\nHow are sales and payments audited?\u003cbr\u003e\nWhat is the deal term?\u003cbr\u003e\nHow are the key terms of the agreement defined?\u003cbr\u003e\nHow are IPRs handled and owned?\u003cbr\u003e\nWho is responsible for commercialization?\u003cbr\u003e\nWho is responsible for development, supply, and manufacture?\u003cbr\u003e\nHow is confidentiality and publication managed?\u003cbr\u003e\nHow are disputes to be resolved?\u003cbr\u003e\nUnder what conditions can the deal be terminated?\u003cbr\u003e\nWhat happens when there is a change of ownership?\u003cbr\u003e\nWhat sublicensing and subcontracting provisions have been agreed?\u003cbr\u003e\nWhich boilerplate clauses does the company insist upon?\u003cbr\u003e\nWhich boilerplate clauses appear to differ from partner to partner or deal type to deal type?\u003cbr\u003e\nWhich jurisdiction does the company insist upon for agreement law?\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"October, 2023 \/ 350 Pages \/ MCW16242883","offer_id":47662132003122,"sku":null,"price":4794.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/hospital-care-collaboration-and-licensing-deals-2016-2023","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}